NO LONGER AVAILABLE - WILL BE REPLACED BY MAY 1, 2010 WITH A SUPERIOR PRODUCT
ORTHO-EYES....(WAS CARNO-SEE)
ORTHO-EYES is a topical N-acetyl-L-carnosine
supplement for the eyes. N-acetyl-L-carnosine is a unique form
of the dipeptide carnosine, which allows for its delivery to
tissues within the eye not accessible to free carnosine
topical supplements. Research supports the ability of topical
carnosine and N-acetyl-L-carnosine supplements to support eye
structure and function.
A Revolution in Orthomolecular Eye Health!
The excitement surrounding the dipeptide Carnosine began when
researchers at the Commonwealth Scientific and Industrial
Research Organization (CSIRO), Australia's premier scientific
research center painstakingly documented the unthinkable: that
carnosine can not only slow down, but actually reverse,
cellular senescence – the process of “aging” at the cellular
level.
Based on their results, scientists “propose that carnosine is an
important component of cellular maintenance mechanisms,” and “favor
the view that it may have a very important role in controlling
cellular homeostasis” – that is, in keeping cells in the
tightly-regulated condition that optimizes their function.
Taking Out the Trash
But how Carnosine exerts these effects remains a mystery. In
test-tube studies, Carnosine protects cells and biomolecules against
a sweeping range of toxic insults. The one protective effect that’s
probably received the most attention in the life extension community
is its ability to protect proteins against glycation – the process
through which sugars bind to proteins and warp their structure,
turning functional proteins into dysfunctional Advanced Glycation
Endproducts (AGEs). But this effect has only been shown to happen in
test tubes: it’s not really clear that the same thing would happen
in a living person, and in fact there’s good reason to believe that
it won’t.
Instead, it appears that Carnosine may attack the same problem from
a different angle, actually boosting the cell’s ability to clear out
damaged proteins once they’re formed. One of the problems with
damaged proteins is that their mangled structures often don’t give
easy access to the enzymes that normally digest worn-out cellular
components, making it difficult for the cell to remove them.
Experimental studies have found that Carnosine reacts with proteins
which have already been damaged by glycation and other assaults on
their structural/functional integrity, forming “carnosylated”
complexes which appear to be more easily removed than the original,
warped protein.
At the same time, other such studies suggest that Carnosine revs up
the proteasome – the cell’s “recycling center” for malformed
proteins. Instead of blocking the formation of AGEs, in other words,
Carnosine might actually help the body to eliminate glycated and
other dysfunctional proteins.
The results at the cellular level are enticing. The question that
begs to be answered next is: how do these effects translate out on a
larger scale – on the health of our tissues and organs – when you
supplement with Carnosine?
Eyes Syruped Shut
Misshapen proteins accumulate across the entire structure of the eye
with “normal” aging, interfering with visual functioning. AGEs, in
particular, play a major role in the universal age-related loss of
eye structure and function, as well as in the more specific
degenerative diseases of the aging eye, such as cataracts, glaucoma,
and age-related macular degeneration (AMD).
Delivering Carnosine directly to the eye itself, then, would be
predicted to be the ideal real-world test case for the test-tube
finding that Carnosine can protect against – and perhaps even
actually undo – the damage wrought by glycation and other
protein-warping mechanisms of aging. New human trials have shown
that topical Carnosine delivers on this promise.
• In an open study protocol, scientists gave Carnosine supplements
to patients in late middle age who had varying degrees of visual
impairment, but no symptomatic cataracts. Over the course of two to
six months, the scientists observed that the use of topical
Carnosine supplementation “appears to alleviate eye tiredness and …
obviously improve eyesight, giving more clear vision.” Users found
that topical Carnosine “could brighten and relax their eyes.” The
improvements were statistically significant.
• In clinical studies involving 109 patients, these scientists found
Carnosine effective in cases of primary and secondary corneal
dystrophy, corneal erosions, trophic keratitis, and bullous
keratopathy, as well as corneal ulcerations and other damage wrought
on the cornea by viral and bacterial infections. The Russian
government accordingly approved topical Carnosine supplementation
for these uses as early as 1997.
• 21 people, with a total of 27 affected eyes, who had suffered
corneal haze following Photorefractive Keratectomy (PRK – a form of
laser surgery) (27 eyes were affected), were given topical Carnosine
three times a day for two months. Fully 57.9% of people using the
Carnosine eye drops experienced a reduction in corneal haze
intensity, accompanied by an improvement in visual acuity; only 14%
of users’ eyes continued to worsen. The positive results appeared in
patients with low to moderate myopia, who had developed moderate
haze (1 to 1.5 on a 3-point scale) within a month of surgery; there
are no known treatments which are effective for late corneal haze of
a higher grade than this.
• In a second, larger, and more rigorous trial, patients who had
just undergone PRK (41 patients (including 73 affected eyes)) or
LASIK (“LAser in-Situ Keratomileusis” – 34 people, 60 eyes) were
given the same thrice-daily regimen of topical Carnosine as was used
in the first trial, while corresponding control groups (41 PRK
patients and 34 LASIK recipients) received Carnosine-free dummy eye
drops. Compared with people applying the placebo solution, the
healing of the corneal epithelium of people supplementing with
Carnosine eye drops took 35 hours less time to regrow – a speeding
of the epithelial re-growth process of nearly a day and a half. Even
better, users of topical Carnosine supplements following LASIK were
one-third less likely to suffer corneal haze than those using the
un-supplemented eye drops!
• In an open investigation, 96 senior citizens who had suffered with
senile cataracts for as little as two to as much as twenty-one years
applied topical Carnosine supplements to their eyes three or four
times a day, for periods ranging from three to six months. At the
end of the study, the researchers found that Carnosine eye drops
lead to improvements in eyesight and lens transparency in the great
majority of patients. They saw improvements in every single one of
the people suffering with early-stage cataracts; and even in mature
senile cataract, a remarkable 80% of the topical Carnosine users
experienced a benefit. The investigators went on to expand on these
preliminary results with the sequential treatment of nearly a
thousand cataract patients – to similar success and with no side
effects observed.
Instead of using Carnosine itself, more recent trials have used
N-acetyl-L-Carnosine, a metabolite of Carnosine, which the body
slowly converts back into free Carnosine, allowing for slower, more
thorough delivery of free Carnosine into the eye’s tissues and
access to areas of the eye where Carnosine itself cannot penetrate.
• In a randomized, double-blind, placebo-controlled study,
scientists first evaluated the baseline state of cataract victims’
eyes. The scientists then randomly handed out either topical
N-Acetyl-L-Carnosine supplements (as a 1% solution) or an
identical-looking placebo solution. A third group of cataract
patients received no eye drops at all.
After just six months, ninety percent of the eyes of people
supplementing with N-Acetyl-L-Carnosine eye drops saw their visual
acuity improve, with the strength of the effect ranging from a
modest gain to a full 100% recovery. In the same period, only 5.7
percent of the eyes of people using the stand-in eye drops were
judged to have improved visual acuity, while over a third (34.7%)
suffered a worsening of acuity, and most (60%) simply retained the
same impaired vision with which they had begun the study. In a
two-year extension, N-Acetyl-L-Carnosine eye drop users were shown
to maintain their improved vision, while the eyesight of those not
receiving the supplement continues to deteriorate.
• On top of the gains in visual acuity, researchers observed that
N-Acetyl-L-Carnosine topical supplementation also clearly improves
glare sensitivity, with 88.9% of N-Acetyl-L-Carnosine eye drop
users’ eyes seeing improvements ranging from 27 to 100% after just
six months; again, the divide separating supplementers from
non-supplementers was unequivocal, with over half (56.3%) of
nonusers’ eyes deteriorating and none getting any better. The glare
sensitivity tests were not repeated at the two-year mark.
• At the end of the full two-year trial, the image analyses showed
that 47.8% of the lenses of N-Acetyl-L-Carnosine topical supplement
users were clearer than they were at the beginning of the trial –
and none had worsened. Meanwhile, none of the people whose eye drops
did not contain N-Acetyl-L-Carnosine showed improvements on the
image analysis, while a predictable 47.4% of the lenses continuing
the hazy slide into blindness.
For the first time, a simple topical treatment was proved to
actually reverse the clouding of the cataracted lens – and the
treatment was not a drug, but a natural substance naturally present
in healthy cells.
The Rest of Us
The results of the many human trials constitute proof-of-concept for
the wider concept that the use of topical Carnosine – and especially
the unique Carnosine metabolite N-Acetyl-L-Carnosine, a biological
“delivery system” for Carnosine – can help the eyes to heal from
damage, and allow the body to remove dysfunctional proteins from the
eye. When you put that together with the fact that malformed
proteins are implicated in nearly every aspect of age-related visual
decline, these studies clearly point to the potential of
Carnosine/N-Acetyl-L-Carnosine eye drops to support the maintenance
of normal, healthy eye structure and function in people whose eyes
are just fine – and whose owners want to keep them that way.
Other ingredients: Sterile water (ophthalmic grade solution pH 6.3
to 6.5), glycerin (lubricant) 1%, carboxymethylcellulose sodium
(lubricant) 0.3%. Buffers: borate, potassium bicarbonate.
Preservative: Purified benzyl alcohol.
AOR guarantees that no ingredients not listed on the label have been
added to the product. Contains no wheat, gluten, corn, nuts, dairy,
soy, eggs, fish or shellfish.
To avoid contamination, do not touch the tip of container to your
eye, your eyelid, or any surface. Replace the cap immediately after
using. Open only one container of solution at a time. Do not allow
other people to use your container. Do not use if seal is broken or
if solution changes color or becomes cloudy. Not recommended for
children under the age of 12 years. If the eye tissue becomes more
inflamed, red, irritated or uncomfortable after using this product,
immediately discontinue the use of product and consult an
eye-physician if necessary. Keep out of the reach of children.